Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Gilead Sciences and keeping the price target at $135.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Gilead Sciences’ strong position in the market. The recent data from the iMMagine-1 presentation at ASH underscores the differentiated profile of anito-cel compared to its competitors, particularly Carvykti. The absence of delayed neurotoxicities and comparable efficacy positions anito-cel favorably for a potential approval in 2026, which is expected to lead to significant market share capture.
Furthermore, the safety profile of anito-cel is promising, with lower incidences of severe adverse effects compared to Carvykti. This, coupled with the novel D-domain’s potential to enhance safety and efficacy, strengthens Gilead’s oncology franchise. The company’s current valuation at a discount to large-cap peers, along with the derisking of its oncology segment, suggests potential for growth, supporting the Buy rating.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $136.00 price target.
Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GILD in relation to earlier this year.